Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study

With 2.1 million unique cases of lung tumors and 1.8 million mortalities in China, advanced solid tumors continue to be the primary source of cancer mortality rates. Nearly two-thirds of lung cancer individuals display advanced-stage tumors at the time of testing, with a 5-year survival ratio of 7%....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuanming, Guo, Runqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941551/
https://www.ncbi.nlm.nih.gov/pubmed/35342409
http://dx.doi.org/10.1155/2022/7794840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941551/
https://www.ncbi.nlm.nih.gov/pubmed/35342409
http://dx.doi.org/10.1155/2022/7794840

Ejemplares similares